See What HealthDay Can Do For You
Contact Us

New Test Estimates Risk of Heart Disease

Agency says best results obtained for black women

MONDAY, Dec. 15, 2014 (HealthDay News) -- A new screening test designed to estimate a person's risk of developing coronary heart disease (CHD) has been approved by the U.S. Food and Drug Administration.

Results of a manufacturer study reviewed by the FDA indicate the test is better at discerning this risk in women, notably black women, the agency said in a news release.

The PLAC Test for Lp-PLA2 Activity, intended for people without a prior history of heart disease, measures a blood biomarker for arterial inflammation, a strong indicator of plaque buildup within arteries that supply blood to the heart.

Heart disease is the leading cause of death in the United States among ethnic groups including blacks, Hispanics and whites. The most common form of heart disease, CHD, leads to the deaths of some 385,000 people each year. About two-thirds of women and half of men who die suddenly of CHD have no prior symptoms, the FDA said.

The new test is produced by diaDexus Inc., based in South San Francisco.

More information

Visit the FDA to learn more.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.